CN103857394A - 四氢甲基嘧啶羧酸的治疗应用 - Google Patents

四氢甲基嘧啶羧酸的治疗应用 Download PDF

Info

Publication number
CN103857394A
CN103857394A CN201280049557.3A CN201280049557A CN103857394A CN 103857394 A CN103857394 A CN 103857394A CN 201280049557 A CN201280049557 A CN 201280049557A CN 103857394 A CN103857394 A CN 103857394A
Authority
CN
China
Prior art keywords
composition
acid
cells
inflammation
neutrophils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280049557.3A
Other languages
English (en)
Chinese (zh)
Inventor
K·翁弗里德
U·赛德里克
J·克鲁特曼
A·比尔施泰因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bitop AG
Original Assignee
Bitop AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bitop AG filed Critical Bitop AG
Publication of CN103857394A publication Critical patent/CN103857394A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280049557.3A 2011-09-09 2012-09-07 四氢甲基嘧啶羧酸的治疗应用 Pending CN103857394A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011113059.8 2011-09-09
DE102011113059A DE102011113059A1 (de) 2011-09-09 2011-09-09 Therapeutische Anwendungen von Ectoin
PCT/EP2012/003757 WO2013034299A1 (de) 2011-09-09 2012-09-07 Therapeutische anwendungen von ectoin

Publications (1)

Publication Number Publication Date
CN103857394A true CN103857394A (zh) 2014-06-11

Family

ID=47115708

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280049557.3A Pending CN103857394A (zh) 2011-09-09 2012-09-07 四氢甲基嘧啶羧酸的治疗应用

Country Status (12)

Country Link
US (1) US20140315869A1 (enExample)
EP (2) EP3287131B1 (enExample)
JP (2) JP6250542B2 (enExample)
CN (1) CN103857394A (enExample)
BR (1) BR112014005414A2 (enExample)
CA (1) CA2848010A1 (enExample)
DE (1) DE102011113059A1 (enExample)
ES (2) ES2657907T3 (enExample)
IN (1) IN2014CN02458A (enExample)
PL (2) PL3287131T3 (enExample)
RU (1) RU2648475C2 (enExample)
WO (1) WO2013034299A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106714797A (zh) * 2014-09-23 2017-05-24 比托普股份公司 用于预防或治疗由微粒物质引起的化妆性或病理性皮疹的溶质和溶质混合物，以及含有至少一种溶质的组合物
CN114425056A (zh) * 2020-10-14 2022-05-03 宁波希诺赛生物科技有限公司 一种用于改善哮喘的干细胞外泌体组合物
CN116570525A (zh) * 2023-06-30 2023-08-11 华熙生物科技股份有限公司 一种具有舒缓功效的组合物及其制备方法和用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160106747A1 (en) * 2008-01-30 2016-04-21 Bitop Ag Treating postoperative mechanical stress with an ectoine
DE102008039231A1 (de) 2008-08-22 2010-02-25 Bitop Ag Verwendung von Glucosylglycerol
DE102014007423A1 (de) * 2014-05-22 2015-11-26 Bitop Ag Zusammensetzung zur Behandlung des Auges
DE102015121050A1 (de) * 2015-12-03 2017-06-08 Bitop Ag Kompatibles Solut oder Solutgemisch zur Verwendung bei der Prävention oder Behandlung von Krankheiten mit Barrieredefekten in Epithelgeweben
DE102016104470A1 (de) 2016-03-11 2017-09-14 Bitop Ag Zusammensetzung zur Förderung der Aktivität von Sirtuinen
WO2019193717A1 (ja) * 2018-04-05 2019-10-10 株式会社資生堂 Ａｓｍｔ発現促進剤
PL448505A1 (pl) * 2024-05-08 2025-11-12 Szkoła Główna Gospodarstwa Wiejskiego w Warszawie Kompozycja o właściwościach barierowych i wirusobójczych wobec koronawirusów, zwłaszcza SARS-CoV-2, sposób jej otrzymywania i zastosowanie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027069A2 (de) * 2007-08-27 2009-03-05 Bitop Ag Osmolyte zur behandlung von allergisch oder viral bedingten atemwegserkrankungen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4244580A1 (de) 1992-12-31 1994-07-07 Galinski Erwin A Verfahren zur in vivo Gewinnung von Inhaltsstoffen aus Zellen
DE4342560A1 (de) * 1993-12-14 1995-06-22 Marbert Gmbh Ectoin und Ectoinderivate als Feuchtigkeitsspender in Kosmetikprodukten
KR20010099865A (ko) * 1998-12-22 2001-11-09 프란시스 제이 메이어 기도 질병 치료용 화합물과 그의 치료 방법 및 기도약물의 전달 방법
ES2204640T3 (es) * 1999-06-12 2004-05-01 Bitop Aktiengesellschaft Fur Biotechnische Optimierung Preparado farmaceutico con contenido en proteinas.
DE10006578C2 (de) * 2000-02-14 2002-10-31 Bitop Ag Verwendung von kompatiblen Soluten als Inhibitoren des enzymatischen Abbaus von makromolekularen Biopolymeren
DE10065986A1 (de) 2000-12-21 2002-07-11 Bitop Gmbh Kompatible Solute als Stabilisatoren für Impfstoffe und Vakzine
DE10330243A1 (de) 2003-07-03 2005-01-20 bitop Aktiengesellschaft für biotechnische Optimierung Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von Arzneimitteln zur äusserlichen Behandlung der Neurodermitis
DE10330768A1 (de) 2003-07-07 2005-02-24 bitop Aktiengesellschaft für biotechnische Optimierung Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von inhalierbaren Arzneimitteln zur Prophylaxe und Behandlung pulmonaler und kardiovaskulärer Erkrankungen, sowie eines Osmolyte als Wirkstoffbestandteil enthaltende Inhalationsvorrichtung
DE102006056766A1 (de) 2006-12-01 2008-06-05 Bitop Ag Verwendung von kompatiblen Soluten

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027069A2 (de) * 2007-08-27 2009-03-05 Bitop Ag Osmolyte zur behandlung von allergisch oder viral bedingten atemwegserkrankungen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BILSTEIN A等: "Therapeutic effect of ectoine in an experimental model of allergic asthma", 《ALLERGY》, vol. 64, no. 90, 31 December 2009 (2009-12-31), pages 313, XP002689778 *
ULRICH SYDLIK等: "The Compatible Solute Ectoine Protects against Nanoparticle-induced Neutrophilic Lung Inflammation", 《AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE》, vol. 180, 31 December 2009 (2009-12-31), pages 29 - 35, XP055186285, DOI: doi:10.1164/rccm.200812-1911OC *
文昭明: "《呼吸系统变态反应疾病诊断治疗学》", 31 July 2002, article "《呼吸系统变态反应疾病诊断治疗学》", pages: 136 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106714797A (zh) * 2014-09-23 2017-05-24 比托普股份公司 用于预防或治疗由微粒物质引起的化妆性或病理性皮疹的溶质和溶质混合物，以及含有至少一种溶质的组合物
CN114425056A (zh) * 2020-10-14 2022-05-03 宁波希诺赛生物科技有限公司 一种用于改善哮喘的干细胞外泌体组合物
CN116570525A (zh) * 2023-06-30 2023-08-11 华熙生物科技股份有限公司 一种具有舒缓功效的组合物及其制备方法和用途

Also Published As

Publication number Publication date
EP3287131A1 (de) 2018-02-28
PL3287131T3 (pl) 2020-10-19
EP3287131B1 (de) 2020-03-04
EP2753330B1 (de) 2017-11-08
JP6250542B2 (ja) 2017-12-20
US20140315869A1 (en) 2014-10-23
ES2657907T3 (es) 2018-03-07
BR112014005414A2 (pt) 2017-04-04
DE102011113059A1 (de) 2013-03-14
IN2014CN02458A (enExample) 2015-08-07
ES2795879T3 (es) 2020-11-25
JP2017197569A (ja) 2017-11-02
JP2014526448A (ja) 2014-10-06
WO2013034299A1 (de) 2013-03-14
CA2848010A1 (en) 2013-03-14
RU2014113906A (ru) 2015-10-20
RU2648475C2 (ru) 2018-03-26
EP2753330A1 (de) 2014-07-16
PL2753330T3 (pl) 2018-05-30
JP6396544B2 (ja) 2018-09-26

Similar Documents

Publication Publication Date Title
CN103857394A (zh) 四氢甲基嘧啶羧酸的治疗应用
JP6795574B2 (ja) Ｒｐｌ５５４を含む液体吸入製剤
KR101805958B1 (ko) 포스포디에스테라제 억제제를 포함하는 건조 분말 제제
JP2017505809A (ja) １５−ｈｅｐｅを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法
JP2009513509A (ja) 肺疾患および心臓血管疾患の予防および治療用の吸入薬の製造のための極限環境細菌から得られたオスモライトの使用、ならびに活性薬剤成分としてオスモライトを含む吸入装置
JP2007518691A (ja) 喘息又は慢性閉塞性肺疾患を治療するための、デヒドロエピアンドロステロン又はデヒドロエピアンドロステロン・スルフェートとロイコトリエン受容体アンタゴニストとの組み合わせ
MD4844C1 (ro) Utilizare a derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi
WO1997001341A1 (en) The combination of topical nasal mast cell stabilizers and topical nasal steroids
WO2022007743A1 (zh) 粘膜给药剂型和其应用
KR20220080127A (ko) 폐 질환을 위한 흡입 가능한 건조 분말 조성물
WO2012147705A1 (ja) トレハロースを含有する炎症性呼吸器疾患の治療剤
CN115397433A (zh) 含有海藻糖或海藻糖衍生物的药物和鼻喷雾剂
EA043839B1 (ru) Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
NZ729796B2 (en) Liquid inhalation formulation comprising rpl554
MXJL05000034A (es) Una formulacion oftalmica topica y su uso.
BR112017005050B1 (pt) Composições farmacêuticas líquidas, nebulizador e usos da composição farmacêutica líquida
NZ616149A (en) Nasal pharmaceutical formulation comprising fluticasone
HK1233919A1 (en) Liquid inhalation formulation comprising rpl554

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140611